Skip to content
Subscriber Only

OptiNose Said to Explore Sale Amid Boom in Health-Care Deals

  • Specialty biotech company may fetch as much as $1.5 billion
  • Backers incluse Avista Capital Partners, Entrepreneurs' Fund

OptiNose Inc., a U.S.-based specialty biopharmaceutical company, is exploring a sale amid the current boom in health-care deals, according to people familiar with the matter.

OptiNose, whose investors include buyout firms Avista Capital Partners, the Entrepreneurs’ Fund and WFD Ventures, is working with JPMorgan Chase & Co. on a process that may value the Yardley, Pennsylvania-based company at $1 billion to $1.5 billion, the people said, asking not to be identified because the plans are private. The sale may attract interest from other specialty pharmaceutical companies, the people said.